Screener
Neuropace, Inc. NPCE Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Neuropace, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Neuropace, Inc.’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:33 PM EDT
- Fiscal quarter
- Q4 FY2030
- Calendar quarter
- Q4 2030
- Accession
- 0001528287-26-000030
FAQ
- What is Neuropace, Inc.'s cash & equivalents?
- Neuropace, Inc. (NPCE) reported cash & equivalents of $12.78M in Q2 2026.
- How has Neuropace, Inc.'s cash & equivalents changed year-over-year?
- Neuropace, Inc.'s cash & equivalents decreased by 44.4% year-over-year, from $22.98M to $12.78M.
- What is the long-term trend for Neuropace, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Neuropace, Inc.'s cash & equivalents has grown at a -4.0% compound annual growth rate (CAGR), from $26.76M to $21.81M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Neuropace, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude